Dasatinib treatment for philadelphia chromosome-positive leukemias

Francois Guilhot, Timothy P. Hughes, Dong Wook Kim, Jorge E. Cortes, Hanna Jean Khoury

Research output: Contribution to journalReview article

Abstract

Dasatinib is a highly potent Bcr-Abl inhibitor that is approved for the treatment of imatinib-resistant or - intolerant chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia. Across a series of phase 2 and 3 trials, dasatinib was associated with durable treatment responses in all phases of the disease and was well tolerated. For this article, the authors reviewed available information on specific side effects associated with the use of dasatinib. On the basis of more than 2 years' experience of dasatinib treatment during clinical trials, they provide practical recommendations for side-effect management.

Original languageEnglish (US)
Pages (from-to)1381-1394
Number of pages14
JournalCancer
Volume115
Issue number7
DOIs
StatePublished - Apr 1 2009
Externally publishedYes

Fingerprint

Philadelphia Chromosome
Leukemia
Pragmatic Clinical Trials
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Dasatinib

Keywords

  • Chronic myeloid leukemia
  • Dasatinib
  • Imatinib
  • Side effects

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Guilhot, F., Hughes, T. P., Kim, D. W., Cortes, J. E., & Khoury, H. J. (2009). Dasatinib treatment for philadelphia chromosome-positive leukemias. Cancer, 115(7), 1381-1394. https://doi.org/10.1002/cncr.24155

Dasatinib treatment for philadelphia chromosome-positive leukemias. / Guilhot, Francois; Hughes, Timothy P.; Kim, Dong Wook; Cortes, Jorge E.; Khoury, Hanna Jean.

In: Cancer, Vol. 115, No. 7, 01.04.2009, p. 1381-1394.

Research output: Contribution to journalReview article

Guilhot, F, Hughes, TP, Kim, DW, Cortes, JE & Khoury, HJ 2009, 'Dasatinib treatment for philadelphia chromosome-positive leukemias', Cancer, vol. 115, no. 7, pp. 1381-1394. https://doi.org/10.1002/cncr.24155
Guilhot, Francois ; Hughes, Timothy P. ; Kim, Dong Wook ; Cortes, Jorge E. ; Khoury, Hanna Jean. / Dasatinib treatment for philadelphia chromosome-positive leukemias. In: Cancer. 2009 ; Vol. 115, No. 7. pp. 1381-1394.
@article{57e8993a6a814a3e9d2892ab07cd7e16,
title = "Dasatinib treatment for philadelphia chromosome-positive leukemias",
abstract = "Dasatinib is a highly potent Bcr-Abl inhibitor that is approved for the treatment of imatinib-resistant or - intolerant chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia. Across a series of phase 2 and 3 trials, dasatinib was associated with durable treatment responses in all phases of the disease and was well tolerated. For this article, the authors reviewed available information on specific side effects associated with the use of dasatinib. On the basis of more than 2 years' experience of dasatinib treatment during clinical trials, they provide practical recommendations for side-effect management.",
keywords = "Chronic myeloid leukemia, Dasatinib, Imatinib, Side effects",
author = "Francois Guilhot and Hughes, {Timothy P.} and Kim, {Dong Wook} and Cortes, {Jorge E.} and Khoury, {Hanna Jean}",
year = "2009",
month = "4",
day = "1",
doi = "10.1002/cncr.24155",
language = "English (US)",
volume = "115",
pages = "1381--1394",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - Dasatinib treatment for philadelphia chromosome-positive leukemias

AU - Guilhot, Francois

AU - Hughes, Timothy P.

AU - Kim, Dong Wook

AU - Cortes, Jorge E.

AU - Khoury, Hanna Jean

PY - 2009/4/1

Y1 - 2009/4/1

N2 - Dasatinib is a highly potent Bcr-Abl inhibitor that is approved for the treatment of imatinib-resistant or - intolerant chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia. Across a series of phase 2 and 3 trials, dasatinib was associated with durable treatment responses in all phases of the disease and was well tolerated. For this article, the authors reviewed available information on specific side effects associated with the use of dasatinib. On the basis of more than 2 years' experience of dasatinib treatment during clinical trials, they provide practical recommendations for side-effect management.

AB - Dasatinib is a highly potent Bcr-Abl inhibitor that is approved for the treatment of imatinib-resistant or - intolerant chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia. Across a series of phase 2 and 3 trials, dasatinib was associated with durable treatment responses in all phases of the disease and was well tolerated. For this article, the authors reviewed available information on specific side effects associated with the use of dasatinib. On the basis of more than 2 years' experience of dasatinib treatment during clinical trials, they provide practical recommendations for side-effect management.

KW - Chronic myeloid leukemia

KW - Dasatinib

KW - Imatinib

KW - Side effects

UR - http://www.scopus.com/inward/record.url?scp=63449094749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63449094749&partnerID=8YFLogxK

U2 - 10.1002/cncr.24155

DO - 10.1002/cncr.24155

M3 - Review article

C2 - 19195046

AN - SCOPUS:63449094749

VL - 115

SP - 1381

EP - 1394

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 7

ER -